Nautilus Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Nautilus Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$396K	Sell	757 -20	-3%	-$10.2K	0.24%	110
2026 Q2	$377K	Hold	777	–	–	0.22%	117
2026 Q1	$347K	Buy	777 +67	+9%	+$31.2K	0.24%	108
2025 Q4	$322K	Buy	710 +50	+8%	+$21.6K	0.21%	124
2025 Q3	$258K	Sell	660 -41	-6%	-$17.1K	0.17%	144
2025 Q2	$312K	Buy	701 +235	+50%	+$108K	0.23%	122
2025 Q1	$226K	Buy	+466	New	+$217K	0.19%	140

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Nautilus Advisors's VRTX Position: Q3 2026 in Review

Nautilus Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 2.6% in Q3 2026, selling an estimated $10.2K and leaving 757 shares worth $396K. The position accounts for 0.24% of the portfolio, ranked #110.

Nautilus Advisors first reported a position in VRTX in Q1 2025 and has held it in 7 quarters since. 440 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Nautilus Advisors held 757 shares of Vertex Pharmaceuticals worth $396K as of Q3 2026.
Nautilus Advisors sold 20 Vertex Pharmaceuticals shares in Q3 2026, an estimated $10.2K.
Vertex Pharmaceuticals made up 0.24% of Nautilus Advisors's portfolio in Q3 2026, its #110 holding.
Nautilus Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
440 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Nautilus Advisors's 13F filing for Q3 2026, filed 7 Oct 2026.